Alexander H Stegh


Affiliation: Northwestern University
Country: USA


  1. Kouri F, Hurley L, Daniel W, Day E, Hua Y, Hao L, et al. miR-182 integrates apoptosis, growth, and differentiation programs in glioblastoma. Genes Dev. 2015;29:732-45 pubmed publisher
    ..Our results indicate that harnessing the anti-tumor activities of miR-182 via safe and robust delivery of 182-SNAs represents a novel strategy for therapeutic intervention in GBM. ..
  2. Stegh A, Brennan C, Mahoney J, Forloney K, Jenq H, Luciano J, et al. Glioma oncoprotein Bcl2L12 inhibits the p53 tumor suppressor. Genes Dev. 2010;24:2194-204 pubmed publisher
    ..Thus, Bcl2L12 is a multifunctional protein that contributes to intense therapeutic resistance of GBM through its ability to operate on two key nodes of cytoplasmic and nuclear signaling cascades. ..
  3. Stegh A, Depinho R. Beyond effector caspase inhibition: Bcl2L12 neutralizes p53 signaling in glioblastoma. Cell Cycle. 2011;10:33-8 pubmed
  4. Calvert A, Chalastanis A, Wu Y, Hurley L, Kouri F, Bi Y, et al. Cancer-Associated IDH1 Promotes Growth and Resistance to Targeted Therapies in the Absence of Mutation. Cell Rep. 2017;19:1858-1873 pubmed publisher
    ..These findings suggest that IDH1 upregulation represents a common metabolic adaptation by GBMs to support macromolecular synthesis, aggressive growth, and therapy resistance. ..